Association Between p53 Arg72Pro Polymorphism and the Risk of Human Papillomavirus-related Head and Neck Squamous Cell Carcinoma: A Meta-analysis

This study aimed to investigate the association between p53 Arg72Pro polymorphism and the risk of humanpapillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) by conducting meta-analysis.The PubMed database was searched for relevant studies until May 30, 2013. Relevant studies were selected anddata were extracted by two independent authors. Overall, subgroup, and sensitivity analyses were then conductedusing the Comprehensive Meta- Analysis v2.2 software. Wild-genotype ArgArg was considered as reference [oddsratio (OR) = 1.00]. Nine studies involving 1071 HNSCC cases were obtained. Meta-analysis results indicatedno association between p53 Arg72Pro polymorphism and the risk of HPV-related HNSCC: for Pro/Pro vs.Arg/Arg, OR = 1.17, 95% confidence interval (CI) = 0.70–1.98; for Arg/Pro vs. Arg/ Arg, OR = 1.25, 95% CI =0.97–1.72; and for (Pro/Pro + Arg/Pro) vs. Arg/Arg, OR = 1.28, 95% CI = 0.95–1.70. These meta-analysis resultswere supported by subgroup and sensitivity analysis results. In conclusions, p53 Arg72Pro polymorphism is apotential marker of HP infection-related HNSCC rather than a susceptibility gene polymorphism.     

Head and Neck Squamous Cell Carcinoma - Comparative Evaluation of Pathological Parameters in Young and Old Patients

Background: To evaluate pathological features of head and neck squamous cell carcinoma (HNSCC) and tocompare these pathological features in patients younger and older than 40 years. Materials and Methods: Allresection specimens of HNSCC between 2010 and 2013 evaluated. Tumor characteristics - grade, location (site)cervical node status, alongwith presence or absence of extranodal extension, lymphovascular invasion, genderand age - were extracted from surgical pathology reports. Results: Among these n=19 patients (21.8%) were40 years or younger and n=68 patients (78.2%) were above 40 years of age. The mean age was 34 (20-40 years)in the younger group and 56 (42-86) in the older group. The most common location of HNSCC in both groupswas the oral cavity. The analysis of histopathological features including grade of tumor, tumor size, extranodalextension and comparison between two groups do not show any significant difference. Conclusions: There are nospecific pathological characteristics of HNSCC in young patients. An interesting observation is that exposure toexpected risk factors is similar in both groups, in younger patients they have less time to act and yet tumors arethe same in terms of tumor size, lymph node status and lymphovascular invasion. Therefore further research isrecommended to look for potentiating factors.     

Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck

The epidermal growth factor receptor (EGFR) is overexpressed in more than 80% of squamous cell cancers of the head and neck (SCCHN). An evolving understanding of the role of EGFR in tumorigenesis has made the receptor an important therapeutic target in SCCHN. Several EGFR inhibitors (EGFRIs) are active in SCCHN, and their use is associated with improvement in progression-free survival and overall survival in various treatment settings. Nevertheless, EGFR inhibition is associated with significant mucocutaneous toxicity that must be balanced against its anticipated efficacy. This review summarizes the relevant clinical trial experience with EGFRIs, with attention to efficacy, toxicity, and methods of selecting patients most likely to benefit from therapy.

Implications for Practice:

Cetuximab and other inhibitors of the epidermal growth factor receptor (EGFR) have entered the medical oncologist’s arsenal against squamous cell carcinoma of the head and neck (SCCHN). They are modestly active as single agents and in combination with chemotherapy and radiotherapy. Despite their efficacy across multiple treatment settings, cetuximab and other EGFR inhibitors (EGFRIs) have not supplanted platinum-based therapies, which remain a standard of care for SCCHN. The modest benefits of EGFRI therapy must take into consideration patient, disease, and treatment characteristics and must be balanced against potential treatment toxicity.     

Response Rate of Cisplatin Plus Docetaxel as Primary Treatment in Locally Advanced Head and Neck Carcinoma (Squamous Cell Types)

Objective: To evaluate the response rate of Cisplatin plus Docetaxel in the treatment of locally advanced head and neck squamous cell carcinomas (HNSCC) at a tertiary care hospital in Karachi, Pakistan. Materials and Methods: It was a longitudinal study, conducted at the Department of Medical Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan from December 2018 to June 2019. One hundred patients of age 14-66 years of age of either gender with histologically proven Squamous Cell Carcinoma of Head and Neck, Stage III and IV (locally advanced) with no distant metastases were included in the study. Patients who were declared unresectable by the otolaryngologist and those with delayed appointment for radiation were given 3 cycles of Induction Chemotherapy with Cisplatin and Docetaxel, both at a dose of 75mg/m2 3 weekly. After 3 cycles, CT scan was repeated to assess the clinical response. Those patients who had partial or complete response as per RECIST criteria were re-assessed by the otolaryngologist and were planned for surgery if disease became resectable while other patients were referred for Concurrent Chemo-Radiation Therapy (CCRT). SPSS version 23 was used to analyze data. Results: The partial response was achieved in majority of the patients after Induction Chemotherapy with Docetaxel and Cisplatin (62%) with a complete response in 12 %. However, 22% showed progression of the disease, and 4% showed stable disease. The most frequent side effects observed were diarrhea (62%) and neutropenia (57%). Conclusion: Induction chemotherapy with Cisplatin and Docetaxel is a promising regimen with good response and favorable toxicity profile and can be considered as a potentially effective outpatient regimen for locally advanced squamous cell carcinoma of head and neck.     

XRCC1 Arg399Gln位点多态性和结直肠癌易感性关系的Meta分析

[目的]探讨X射线交叉互补修复基因1（X-ray repair cross-complementing group1,XRCC1）的399位点（Arg399Gln）多态性与结直肠癌（CRC）易感性的关系。[方法]检索中国生物医学数据库（CBM）、PubMed、Springer等数据库,获取有关XRCC1Arg399Gln多态性同结直肠癌易感性关系的病例对照研究并进行Meta分析,以病例组及对照组XRCC1Arg399Gln等位基因分布的比值比（OR）为效应指标,应用Meta分析软件Review Manager（version5.0.10）对各研究原始数据进行统计处理及异质性检验,计算合并OR值及其95%可信区间（95%CI）。[结果]纳入11项病例对照研究,共2287例结直肠癌患者和3485例对照,Meta分析结果显示,Gln/Gln vs.Arg/Arg OR=1.12,95%CI为0.76～1.65,Z=0.58,POR=0.56;Gln/Gln＋Arg/Gln vs.Arg/Arg OR=1.11,95%CI为0.85～1.44,Z=0.78,POR=0.43;Gln/Glnvs.Arg/Arg＋Arg/Gln OR=1.07,95%CI为0.79～1.46,Z=0.43,POR=0.67;Arg/Gln vs.Arg/Arg OR=1.14,95%CI为0.88～1.48,Z=1.02,POR=0.31。[结论]XRCC1Arg399Gln多态性与结直肠癌易感性之间无显著相关性。     

乙酰肝素酶和VEGF在头颈鳞癌组织中的表达及其临床意义

目的: 探讨HPSE、VEGF蛋白在头颈鳞癌组织中的表达及其临床意义,并探讨其相关性。 方法: 采用免疫组织化学(S-P法)和流式细胞检测方法对62例头颈鳞癌组织中HPSE和VEGF蛋白的表达进行检测,并采用计算机图像分析进行定量分析。 结果: HPSE和VEGF蛋白在头颈鳞癌组织中的表达均高于正常粘膜组织(P<0.01);淋巴结转移组鳞癌组织中HPSE和VEGF的表达高于无淋巴结转移组(分别为P<0.05和P<0.01);淋巴结转移组中原发灶与转移灶中HPSE和VEGF的表达差异无统计学意义(P值均>0.05),但原发灶与转移灶之间的表达成正相关(分别r=0.9162,r=0.9278,P均<0.01);HPSE和VEGF的表达均与头颈鳞癌组织中TNM分期有关(P均<0.05);HPSE与VEGF在头颈鳞癌组织中的表达呈正相关关系(r=0.7602,P<0.01);HPSE和VEGF的表达分别与患者的生存期存在负相关关系(分别为r=-0.647,r=-0.568,P均<0.01)。 结论: 头颈鳞癌组织中HPSE和VEGF蛋白的表达与TNM分期、淋巴结转移和预后有密切关系,两种基因起头颈鳞癌发生、发展中起重要作用。     

Updated Assessment of the Association of the XRCC1 Arg399Gln Polymorphism with Lung Cancer Risk in the Chinese Population

Background: Published studies have reported relationships between X-ray repair cross-complementing group1 (XRCC1) Arg399Gln polymorphism and lung cancer risk in Chinese population. However, the epidemiologicalresults remained controversial. The objective of this study was to clarify the association of XRCC1 Arg399Glnpolymorphism with lung cancer risk in the Chinese population. Materials and Methods: Systematic searches wereperformed through the database of Medline/Pubmed, Web of Science, Embase, CNKI and WanFang MedicalOnline. Odds ratios (ORs) with 95% confidence interval (95%CI) were calculated to estimate the strength ofthe association. Results: Overall, we observed an increased lung cancer risk among subjects carrying XRCC1codon 399 Gln/Gln genotype (OR=1.36, 95%CI: 1.09-1.71) in the Chinese population on the basis of 19 studieswith 5,416 cases and 5,782 controls. We did not observe any association between XRCC1 codon 399 Arg/Gln andArg/Gln+Gln/Gln polymorphisms and lung cancer risk (OR=1.00, 95%CI: 0.92-1.08 and OR=1.05, 95%CI: 0.97-1.13, respectively). Limiting the analysis to studies with controls in agreement with Hardy-Weinberg equilibrium(HWE), we observed an increased lung cancer risk among subjects carrying XRCC1 codon 399 Gln/Gln genotype(OR=1.18, 95%CI: 1.01-1.38). When stratified by source of control, we observed an increased lung cancer riskamong subjects carrying XRCC1 codon 399 Arg/Gln+Gln/Gln genotype on the basis of hospitalized patient-basedcontrols (OR=1.21, 95%CI: 1.04-1.42) and among subjects carrying XRCC1 codon 399 Gln/Gln genotype onthe basis of healthy subject-based controls (OR=1.22, 95%CI: 1.04-1.43). Conclusions: Our findings indicatedthat certain XRCC1 Arg399Gln variants might affect the susceptibility of lung cancer in Chinese population.Larger sample size studies are required to confirm our findings.     

Association of XRCC1 Arg399Gln Polymorphism with Colorectal Cancer Risk: A HuGE Meta Analysis of 35 Studies

Background: Non-synonymous polymorphisms in XRCC1 hase been shown to reduce effectiveness of DNArepair and be associated with risk of certain cancers. In this study we aimed to clarify any association betweenXRCC1 Arg399Gln and colorectal cancer (CRC) risk by performing a meta-analysis of published case-controlstudies. Materials and Methods: PubMed and Google Scholar were searched to explore the association betweenXRCC1 and CRC. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate theassociation strength. Publication bias was assessed by Egger’s and Begg’s tests. Results: Up to January 2015, 35case control studies involving 9,114 CRC cases and 13,948 controls were included in the present meta-analysis.The results showed that the Arg399Gln polymorphism only under an allele genetic model was associated withCRC risk (A vs. G: OR 0.128, 95% CI 0.119-0.138, p<0.001). Also, this meta-analysis suggested that the XRCC1Arg399Gln polymorphism might associated with susceptibility to CRC in Asians (A vs G: OR 0.124, 95% CI0.112-0.138, p<0.001) and Caucasian (A vs G: OR 0.132, 95% CI 0.119-0.146, p<0.001) only under an allele geneticmodel. Conclusions: This meta-analysis confirms the association between XRCC1 Arg399Gln polymorphismand CRC risk and suggests that the heterogeneity is not strongly modified by ethnicity and deviation from theHardy-Weinberg equilibrium.     

XRCC1基因Arg399Gln多态与胃癌临床病理因素的关系

背景与目的：DNA修复基因XRCC1参与DNA损伤的碱基切除修复途径（BER），其Arg399Gln多态可以改变蛋白产物的DNA修复效能．本研究探讨XRCC1基因Arg399Gln多态与胃癌临床病理因素的关联性。方法：采用聚合酶链反应PCR-变性高效液相色谱分析（denaturing high performance liquid chromatography，DHPLC）方法对102例胃癌患者进行XRCC1基因Arg399Gln多态的基因型分析，比较基因型分布与胃癌组织临床病理特征之间的关系。结果：XRCC1基因Arg399Gln多态的Arg／Arg（GG），Arg／Gin（G→A）及Gin／Gin（AA）基因型在病例组中的分布频率分别为46（45．1％），48（47．1％），8（7．8％）；含至少一个399Gln的基因型患胃癌的年龄明显要小（P=0．07）；Arg399Gln多态性与胃癌的病理类型、肿瘤部位、组织分级、浸润深度及淋巴结转移、临床分期间没有显著关系（P〉0．05）。结论：XRCC1基因399Gln等位基因可能是胃癌早年发病的危险因素之一；但不是判断胃癌侵袭相关的生物学行为的预测指标。这些结果还需要大样本量的胃癌分子流行病学研究加以验证。     

The Codon 399 Arg/Gln XRCC1 Polymorphism is Associated with Lung Cancer in Indians

Background: The XRCC1 (X-ray repair cross complimenting group-I) gene in BER (base excision repair)pathway is essential for DNA repair process. Polymorphisms in this gene are associated with variations in the repairefficiency which might predispose individuals to development of various cancers. Two variants of XRCC1gene(at codon 399), Gln/Gln and Arg/Gln, have been shown to be related to lowered DNA repair capacity andincreased genomic instability in multiple studies. Hence our investigation focused on genotyping these variantsto correlate with other multiple risk factors in lung cancer (NSCLC) patients since we hypothesized that thesevariants of the XRCC1 gene might influence disease susceptibility. Materials and Methods: We examined thefrequency of the polymorphism in one hundred cases and an almost equal number of controls after recordingtheir demographics with a structured questionnaire. Genomic DNA from blood samples was extracted for PCRstudies, followed by RFLP to determine the variants. The significance of the data was statistically analyzed.Results: The three genotypes in cases and controls were Arg/Arg (40% and 54.45%); Gln/Gln (19% and 9.90%),and Arg/Gln (41.0% and 35.64%) respectively. Among these 3 genotypes, we found Gln/Gln and Arg/Gln toshow association with lung cancer. Correlating these genotypes with several parameters, we also found that thesetwo variants were associated with risk in males (p<0.05) and with smoking habits (p<0.05). In females Arg/Glngenotype showed association with stage of the disease (p=0.04). This is the first report in South Indian scenariowhere Arg399Gln genotypes were found to be associated with stage of the disease in females. Conclusions: Itis concluded that XRCC1 genotypes Gln/Gln and Arg/Gln may influence cancer susceptibility in patients withsmoking habits and these functional SNPs in XRCC1 gene may act as attractive candidate biomarkers in lungcancer for diagnosis and prognosis.     

Overall Survival of Filipino Patients with Squamous Cell Carcinoma of the Head and Neck: A Single-Institution Experience

This paper is the first to present the incidence and overall survival of patients with squamous cell carcinomaof the head and neck (SCCHN) from the extreme northern part of the Philippines. We retrospectively retrievedthe records of patients with histologically-confirmed squamous cell carcinoma of the oral cavity, oropharynx,hypopharynx and larynx at the Mariano Marcos Memorial Hospital and Medical Center, Ilocos Norte, Philippines,from 2003 to 2012 and analysed prognostic factors associated with survival. Of the 150 cases, only 80 (53.3%) werestill living when the study was terminated. Median age at initial diagnosis was 61.5 years and the male to femaleratio was 7:3. The majority of the cases had tumours in the oral cavity (50.7%), followed by the larynx (36.7%).Sex (log rank=1.94, p value/α=0.16), tumor site (log rank=0.02, p value/α=0.90), tumor grade (log rank=1.74, pvalue/α=0.42), and node stage (log rank=0.07, p value/α=0.80) were not shown to be associated with the survivalof our cases. Only 45 (30.0%) had no regional lymph node involvement (N0) at presentation and 12 (8.0%) hadalready developed distant metastases. Among the 150 patients, 71 (47.3%) were not able to receive treatment ofany kind. Oddly, treatment (log rank=1.65, p value/α=0.20) was also shown to be not associated with survival.The survival rate of those who underwent surgery, radiotherapy, or both was not statistically different fromthose who did not receive any treatment. Only the tumor stage (log rank=4.51, p value/α=0.03) was associatedwith patient survival. The overall mean survival was 49.3 months, with survival rate diminishing from 88.3%during the 1st year to 1.80% by end of the study. This relatively low survival rate of our cases only reflects theirpoor access to quality diagnostic and treatment facilities.     

Association Between the XRCC3 T241M Polymorphism and Head and Neck Cancer Susceptibility: a Meta-analysis of Case-control Studies

Background: To evaluate the role of the X-ray repair cross complementing group 3 (XRCC3) T241Mpolymorphism in head and neck cancer susceptibility. Materials and Methods: We performed a meta-analysis ofall available studies, which included 3,191 cases and 5,090 controls. Results: Overall, a significant risk effect of theT241M polymorphism was not found under homologous contrast (MM vs TT: OR=1.293, 95% CI=0.926-1.805;TM vs TT: OR=1.148 95% CI=0.930-1.418) and recessive models (MM vs TT+TM): OR=1.170, 95% CI=0.905-1.512, but a significantly increased risk was observed under a dominant model (MM+TM vs TT): OR=1.243,95% CI=1.001-1.544. In stratified analyses, there were no significant associations for Asians or Caucasians.Conclusion: Our meta-analysis suggested the XRCC3 241M allele (MM+TM) might act as a head and neckcancer risk factor among all subjects, and the effect of T241M polymorphism on head and neck susceptibilityshould be studied with a larger, stratified population.     

Serum Level of Mast Cell Tryptase in Patients with Oral Squamous Cell Carcinoma: Lack of Correlation with Clinicopathologic Factors

Background: Mast cells can influence tumor progression via different pathways and increased mast celldensity has been demonstrated in oral squamous cell carcinoma (OSCC). It has been shown that the serumtryptase level is elevated with some malignant tumours and may thus be a useful parameter. However, there areno data available about OSCC. The main aim of this study was the evaluation of mast cell tryptase (MCT) levelin OSCC patient serum. Materials and Methods: In this cross-sectional, analytic study, the circulating levels ofMCT were assessed in sera of 55 OSCC patients and 34 healthy individuals with ELISA technique. Results: Theserum MCT level in OSCC patients was 12-14 ng/ml, which was not significantly higher than the healthy controlgroup. While the serum level of MCT was higher with larger tumours, there was no apparent correlation withclinico-pathological features such as patient age, gender, tumor location, stage, nodal status, distant metastasis,histological grade and smoking. Conclusions: Our findings showed that despite the results obtained from studiesof other malignant tumors, serum level of MCT in OSCC patients could not be a credited as a reliable indicatorof the presence or progression of tumours.     

Associations Between XRCC1 Arg399Gln,Arg194Trp,and Arg280His Polymorphisms and Risk of Differentiated Thyroid Carcinoma: A Meta-analysis

Background: Associations between Arg399Gln, Arg194Trp and Arg280His polymorphisms of the XRCC1 geneand risk of differentiated thyroid carcinoma (DTC) have been widely studied but the findings are contradictory.Methods: We performed a meta-analysis in the present study using STATA 11.0 software to clarify any associations.Electronic literature databases and reference lists of relevant articles revealed a total of 10, 6 and 6 publishedstudies for the Arg399Gln, Arg194Trp and Arg280His polymorphisms, respectively. Results: No significantassociations were observed between Arg399Gln and DTC risk in all genetic models within the overall andsubgroup meta-analyses, while the Trp/Trp vs Arg/Arg and recessive model of the Arg194Trp polymorphismwas associated with DTC susceptibility, and the dominant model of Arg280His polymorphism contributed toDTC susceptibility in Caucasians. Conclusions: Our meta-analysis suggests that XRCC1 Arg194Trp may be arisk factor for DTC development.     

Gene Polymorphism of XRCC1 Arg399Gln and Cervical Carcinoma Susceptibility in Asians: A Meta-analysis Based on 1,759 Cases and 2,497 Controls

Many epidemiological studies in Asian populations have investigated associations between the Arg399Glngene polymorphism of X-ray repair cross complementing gene 1 (XRCC1) and risk of cervical carcinoma, butno conclusions have been available because of controversial results. Therefore a meta-analysis was conducted forclarification. Relevant studies were identified by searching the Pubmed, Embase, the Web of Science, CochraneCollaboration’s database, Chinese National Knowledge Infrastructure (CNKI), Wanfang database and ChinaBiological Medicinse (CBM) until September, 2012. A total of eight studies were included in the present metaanalysis,which described 1,759 cervical carcinoma cases and 2,497 controls. Odds ratios (ORs) and corresponding95% confidence intervals (95%CIs) as effect size were calculated by fixed-effect or random-effect models.The overall results indicated that the XRCC1-399G/A polymorphism was marginally associated with cervicalcarcinoma in Asians: OR (95%CI): 1.16 (1.07, 1.26) in the G/A vs G/G inheritance model, 1.24 (0.87, 1.76)inA/A vs G/G inheritance model, 1.13 (1.01, 1.27) in the dominant inheritance model and 1.18 (0.94, 1.47) in therecessive inheritance model. Subgroup analyses on sample size showed no significant correlation in the smallsamplesize group but the large-sample size group was consistent with the outcomes of overall meta-analysis.In the subgroup analysis by regions, we only found significant association under the G/A vs G/G inheritancemodel in the Chinese population. For the non-Chinese populations, no correlation was detected in any geneticinheritance model. In the Asian populations, XRCC1-399G/A gene polymorphism was implied to be associatedwith cervical carcinoma.     

Influence of Tumor Site on Survival in Young Patients with Head and Neck Squamous Cell Carcinoma

The number of patients under the age of 45 diagnosed with head and neck squamous cell carcinomas (HNSCC) is increasing, probably due to the incidence of oropharyngeal cancers. Comparisons of HNSCC in young and old patients regarding tumor site and survival in sample sizes of relevance are rarely published. The aim of the study was to analyze the differences in survival between age groups dependent on tumor site and the influence of oropharyngeal cancers on the rising rates of HNSCC in the young. The records of 4466 patients diagnosed with HNSCC were reviewed retrospectively. Patients younger than 45 years were divided further into four subgroups for specific age differences in the young. The influences of patient and clinicopathological characteristics on survival were assessed using Kaplan–Meier analyses. Among the patient cohort, 4.8% were younger than 45 years. Overall survival (OS) in these patients was better, with a 5-year OS of 66.1% (vs. 46.4%), while relapse-free survival (RFS) was better in the older patient population, with a 5-year RFS of 74.9% (vs. 68.1%). Decreased RFS in the young was found for advanced tumor stages and tumor sited at the larynx. Hypopharynx and advanced stages were independent risk factors for OS under 45 years. Overall, 44.4% of all HNSCC in patients under 30 years were nasopharyngeal cancers, and incidence decreased with age. The incidence of oropharyngeal cancers increased significantly with age. Better OS in the young may be explained by lower tumor and disease stages, whereas oropharyngeal tumors and HPV were not found to cause rising rates of HNSCC. Laryngeal malignancies in young patients might be related to an increased malignant potential and should, consequently, be treated as such.     

头颈鳞癌的术前化疗效果

[目的]研究术前化疗能否提高手术切除率,降低局部复发率。［方法］104例头颈鳞癌病人分成试验组（58例）：术前化疗 手术 术后放疗组;对照组（46例）：手术 术后放疗,但不用术前化疗。手术方式为原发癌切除 颈淋巴结清扫术,用或不用肌皮瓣修复头颈部组织缺损。术后放疗剂量50Gy～60Gy。术前化疗用PFP方案即DDP＋5－Fu＋PYM。［结果］试验组部分缓解67.2%,微效17.2%。试验组和对照组3年局部复发率分别为27.6%、52．2％（P＜0.01）;但3年内远处转移率无差异,分别为34．5%、34．8%,中位生存期分别为23个月和22个月,3年生存率分别为65．5%和56．5%（P＞0.05）。［结论］术前新辅助化疗,可以缩小瘤体,提高手术切除率,减少局部复发。     

XRCC1基因Arg399Gln多态性与中国人群神经胶质瘤易感性Meta分析

目的:探讨XRCC1基因Arg399Gln (G/A)多态性与中国人群神经胶质瘤易感性的关系.方法:计算机检索Pubmed、EMBASE、中国知网、万方期刊、维普等中英文数据库,检索2014年10月之前公开发表的相关文献,对符合标准的文献采用NOS量表评价文献质量,应用RevMan5.1软件进行Meta分析.结果:共纳入9篇与XRCC1基因Arg399Gln多态性与神经胶质瘤易感性相关的病例对照研究,包括7 131例患者,其中病例组3 428例,对照组3 703例,NOS评分≥6分为高质量文献,仅2项研究质量评分＜6.Meta分析结果显示携带A等位基因可增加中国人群神经胶质瘤的患病风险(OR=1.20,95％CI:1.04～1.38,P=0.01).结论:中国人群中XRCC1基因Arg399Gln (G/A)多态性与神经胶质瘤的易感性存在相关性.     

An updated meta-analysis between the association of XRCC1 Arg399Gln polymorphism and hepatocellular carcinoma risk

Background: Various studies have evaluated the relationship between X-ray repair cross-complementinggroup 1 (XRCC1) Arg399Gln polymorphism and hepatocellular carcinoma (HCC) risk, but the conclusionshave been inconsistent and underpowered. The purpose of this updated meta-analysis was to examine whetherXRCC1 Arg399Gln polymorphism confers susceptibility to HCC. Methods: Eligible studies extracted fromPubMed, Embase, Cochrane Library, VIP (chinese) and CNKI (chinese) up to November 2013 were included inthe study. Pooled odds ratio (OR) together with their 95% confidence interval (CI) were estimated to evaluateXRCC1 Arg399Gln polymorphism and HCC risk. Results: Finally, 21 studies with 4,170 cases and 5,030controls were involved in our meta-analysis. The results demonstrated that there was significant associationbetween Arg399Gln polymorphism and HCC risk under two contrast models in overall populations (AG vs GG:OR=1.265, 95%CI=1.036-1.545, p=0.021; AA+AG vs GG: OR=1.240, 95%CI=1.021-1.506, p=0.030). In subgroupanalyses, significant association was found in Asians (A vs G: OR=1.175, 95%CI=1.013-1.362, p=0.033; AG vsGG: OR=1.317, 95%CI=1.070-1.622, p=0.009; AA+AG vs GG: OR=1.289, 95%CI=1.055-1.575, p=0.013) andCaucasians (A vs G: OR=0.591, 95%CI=0.361-0.966, p=0.036; AA+AG vs GG: OR=0.468, 95%CI=0.234-0.934,p=0.031). Conclusions: The results suggest that XRCC1 Arg399Gln polymorphism may increase HCC riskespecially among Asians. However, XRCC1 Arg399Gln polymorphism might act as a protective role againstHCC among Caucasians.